Apolipoprotein biopolymer marker indicative of normal human
The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with reference to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of said at least one disease state relative to recognition of the presence and/or the absence of said biopolymer, predict disease risk assessment, and develop therapeutic avenues against said disease.
1 . A method for screening for efficacy of disease process modulating agents for Type II diabetes comprising:
(a) providing a sample of bodily fluid containing a biopolymer marker consisting of SEQ ID NO:1 or consisting of SEQ ID NO:2;
(b) adding a quantity of said agent sufficient to interact with said biopolymer marker consisting of SEQ ID NO:1 or consisting of SEQ ID NO:2; and
(c) determining the presence of an interaction between said agent and said biopolymer marker consisting of SEQ ID NO:l or consisting of SEQ ID NO:2;
wherein said interaction is determinative of efficacy of said disease process modulating agent.
2 . A method for diagnosing Type II diabetes by determining the presence of a biopolymer marker consisting of SEQ ID NO:1 or consisting of SEQ ID NO:2 comprising:
(a) conducting mass spectrometric analysis on a sample obtained from a patient in a manner effective to maximize analysis of peptide fragments contained therein;
(b) comparing a mass spectral profile of said biopolymer marker consisting of SEQ ID NO:1 or consisting of SEQ ID NO:2 to mass spectral profiles of peptides obtained and analyzed from said sample; and
(c) confirming the presence of said biopolymer marker consisting of SEQ ID NO:1 or consisting of SEQ ID NO:2 in said sample by identifying a mass spectral profile having an ion peak at about 1624 daltons for said biopolymer marker consisting of SEQ ID NO:1 or by identifying a mass spectral profile having an ion peak at about 1552 daltons for said biopolymer marker consisting of SEQ ID NO:2; wherein the presence of said biopolymer marker consisting of SEQ ID NO:1 or consisting of SEQ ID NO:2 is diagnostic for Type II diabetes.
3 . A method for diagnosing Type II diabetes comprising:
(a) providing a sample; and
(b) determining the presence of a biopolymer marker consisting of SEQ ID NO:1 or consisting of SEQ ID NO:2 in said sample;
wherein the presence of said biopolymer marker consisting of SEQ ID NO:1 or consisting of SEQ ID NO:2 is diagnostic for Type II diabetes.
4 . The method of claim 3 , wherein said sample is an unfractionated body fluid or a tissue sample.
5 . The method of claim 3 , wherein said sample is selected from the group consisting of blood, blood products, urine, saliva, cerebrospinal fluid, and lymph.
6 . The method of claim 3 , wherein said sample is obtained from a human.